Natera (NASDAQ:NTRA) Insider Sells 898 Shares of Company Stock

Key Points

• Natera insider John Fesko sold 898 shares at an average price of $426.34, totaling approximately $382,853. The sale, conducted under a Rule 10b5-1 plan, covered tax withholding obligations; Fesko still owned 195,578 shares afterward.
• Natera shares reached $436, near their 52-week high of $437.41, with the stock trading well above its 50-day and 200-day moving averages. The company’s latest quarterly revenue rose 37.7% year over year and exceeded analysts’ expectations, although it remained unprofitable.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $394.31. However, investors face potential volatility ahead of the company’s November 5 quarterly results, while some analysis suggests the shares may be overvalued.

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 898 shares of Natera stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $426.34, for a total transaction of $382,853.32. Following the transaction, the insider directly owned 195,578 shares of the company's stock, valued at approximately $83,382,724.52. This trade represents a 0.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Tuesday, October 27th, John Fesko sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $317,086.00.
• On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01.
• On Monday, August 3rd, John Fesko sold 295 shares of Natera stock. The shares were sold at an average price of $267.99, for a total transaction of $79,057.05.

Natera Stock Performance

Shares of NTRA traded up $11.58 during mid-day trading on Thursday, reaching $436.00. The company had a trading volume of 1,325,469 shares, compared to its average volume of 1,585,948. The firm has a 50-day moving average price of $375.27 and a 200 day moving average price of $265.54. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The firm's revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.74) EPS. Equities research analysts anticipate that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently added to or reduced their stakes in NTRA. Trust Co. of Vermont purchased a new position in Natera during the second quarter valued at $26,000. Elevation Wealth Partners LLC purchased a new stake in Natera in the 2nd quarter worth $30,000. Continuum Advisory LLC purchased a new stake in Natera in the 2nd quarter worth $33,000. Rakuten Securities Inc. bought a new position in shares of Natera during the 2nd quarter valued at about $35,000. Finally, Burkett Financial Services LLC bought a new position in shares of Natera during the 3rd quarter valued at about $57,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on NTRA. Rothschild & Co Redburn initiated coverage on Natera in a research report on Tuesday, September 8th. They issued a "buy" rating and a $385.00 price target for the company. Roth Capital assumed coverage on shares of Natera in a report on Thursday, October 22nd. They issued a "buy" rating and a $475.00 target price for the company. Evercore reiterated an "outperform" rating and issued a $300.00 target price on shares of Natera in a research note on Monday, July 6th. Leerink Partners set a $330.00 price target on shares of Natera in a report on Friday, August 7th. Finally, Canaccord Genuity Group raised their price target on shares of Natera from $375.00 to $500.00 and gave the company a "buy" rating in a research report on Monday, October 19th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Natera presently has an average rating of "Moderate Buy" and a consensus price target of $394.31.

Natera News Summary

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera presented 25 abstracts at the ESMO oncology conference, highlighting additional Signatera data and supporting the test’s potential commercial and clinical adoption. Natera presents 25 ESMO abstracts
• Positive Sentiment: Investors reacted favorably to Signatera clinical and regulatory wins, which could strengthen Natera’s competitive position in minimal residual disease testing and support future revenue growth. Investors React to Signatera Wins
• Positive Sentiment: The third-quarter outlook centers on continued Signatera volume growth, higher test prices, regulatory progress and expanding Medicare coverage that could benefit Natera’s organ-health business. NTRA Q3 Earnings Preview
• Neutral Sentiment: Natera will release third-quarter 2026 results on November 5 after the market closes, giving investors a near-term catalyst to assess testing volumes, reimbursement trends and profitability. Natera Q3 Results Announcement
• Negative Sentiment: Zacks cautions that Natera may report negative earnings and lacks the typical combination of estimate revisions and momentum associated with a likely earnings beat, raising the risk of volatility around the report. Natera Earnings Beat Outlook
• Negative Sentiment: One valuation analysis estimates NTRA could be about 32% below fair value based on ESMO-related data, suggesting the stock’s gains may have outpaced its fundamentals. Natera Fair Value Analysis
• Negative Sentiment: Two company officers disclosed plans to sell a combined 1,768 shares, including 771 shares valued at approximately $312,000; the transactions are relatively small but may modestly weigh on sentiment. John Fesko Share Sale Solomon Moshkevich Share Sale

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.